Table 3.
TEAMS | Symphony | Total | 95% CI | χ2 | p Value | df | OR (95% CI)* | |
---|---|---|---|---|---|---|---|---|
Patient level, including omission | n/N (%) | n/N (%) | n/N (%) | |||||
Generic drug name used† | 73/164 (44.5) | 3/25 (12) | 76/189 (40.2) | (33.9 to 47.1) | 9.538 | 0.001 | 1 | 0.17 (0.05 to 0.59) |
Dose indicated† | 76/164 (46.3) | 3/25 (12) | 79/189 (41.8) | (34.9 to 48.7) | 10.516 | 0.001 | 1 | 0.16 (0.05 to 0.55) |
Frequency of administration indicated† | 76/164 (46.3) | 2/25 (8) | 78/189 (41.3) | (34.4 to 48.7) | 13.157 | 0.000 | 1 | 0.10 (0.02 to 0.44) |
Duration of therapy† | 64/164 (39) | 3/25 (12) | 67/189 (35.4) | (28.6 to 42.3) | 6.923 | 0.006 | 1 | 0.21 (0.06 to 0.74) |
Changes on discharge summary | 23/114 (20.2) | 0/16 (0) | 23/130 (17.7) | (10.8 to 24.6) | – | 0.074‡ | 1 | 0.85 (0.79 to 0.92) |
Reason for change to preadmission medication | 24/47 (51.1) | 1/1 (100) | 25/48 (52.1) | (37.5 to 64.6) | – | – | – | – |
Indication(s) for medication newly started† | 54/129 (41.9) | 12/16 (75) | 66/145 (45.5) | (37.2 to 53.8) | 6.304 | 0.012 | 1 | 4.17 (1.28 to 13.62) |
Overall compliance with all medication criteria | 33/165 (20) | 3/25 (12) | 36/190 (18.9) | (13.7 to 25.2) | – | 0.432 | 1 | 0.55 (0.15 to 1.93) |
*Likelihood of TEAMS compliance relative to Symphony compliance.
†Statistically significant.
‡Fisher’s exact reported as >20% of expected frequencies were <5.
TEAMS, Tallaght Education and Audit Management System.